Targeting Cancer at its Core: Cellular and Genetic Approaches Via CAR-T Cell Therapy CAR-T Cell Therapy of Cancer

Cancer has recently overtaken other conditions as the foremost cause of death worldwide. While numerous conventional treatment modalities and cytotoxic immunotherapies are available, the intricate nature of tumor biology— driven by a multitude of genetic and cellular factors underlying tumorigenesis and metastasis—necessitates the development of advanced treatment approaches capable of acting on cellular as well as genetic fronts. Amid these advancements, Chimeric Antigen Receptor (CAR) T-cell therapy has risen as a pioneering frontier in the domain of T-cell engineering. Here, T cells obtained from the patient are engineered ex vivo to carry synthetic receptors designed to recognize tumor-associated antigens. A key feature is that these modified receptors can identify tumor antigens without requiring MHC presentation. Recently, CAR-T cell therapy has achieved significant clinical milestones, inducing remission in up to 80% of patients with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL) and certain subtypes of non-Hodgkin lymphoma, such as large B-cell lymphoma. The anti-CD19 CAR design, UCART19, has demonstrated remarkable therapeutic potency in managing relapsed or refractory hematologic malignancies. Furthermore, other surface antigens, including CD20 and CD22, prevalent in various leukemias and lymphomas, are being actively explored as therapeutic targets, with multiple clinical trials underway. Although its application is presently concentrated on blood cancers, the integration of advanced modalities—such as bispecific CARs, tandem CARs, inhibitory CARs, multi-antigen targeting, CRISPR-based gene editing, and nanoparticle-mediated delivery—holds the promise of significantly enhancing its efficacy. These advancements may extend its utility to both hematologic and solid tumors, offering a treatment paradigm that is not only rapid and precise but also safer compared to traditional modalities. The purpose of this review is to offer an in-depth analysis of the benefits and emerging developments in CAR T-cell immunotherapy, while underscoring its rising advantage over conventional treatments like chemotherapy and radiotherapy.